Treatment of 22Q11.2 deletion syndrome with cannabidiol
US12186282B2 · kind B2 · utility
0Cited by
19References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 30, 2022 |
| Grant date | Jan 7, 2025 |
| Priority date | — |
| Expiry date | Dec 21, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q 11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q 11.2 deletion syndrome are treated in the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.